Insulet Corporation (PODD)
| Market Cap | 16.56B |
| Revenue (ttm) | 1.87B |
| Net Income (ttm) | 395.30M |
| Shares Out | 70.04M |
| EPS (ttm) | 5.44 |
| PE Ratio | 43.47 |
| Forward PE | 71.57 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 515,197 |
| Open | 236.59 |
| Previous Close | 236.59 |
| Day's Range | 234.76 - 238.99 |
| 52-Week Range | 128.68 - 243.98 |
| Beta | 1.21 |
| Analysts | Buy |
| Price Target | 236.67 (+0.08%) |
| Earnings Date | Nov 7, 2024 |
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch... [Read more]
Financial Performance
In 2023, Insulet's revenue was $1.70 billion, an increase of 30.02% compared to the previous year's $1.31 billion. Earnings were $206.30 million, an increase of 4384.78%.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for PODD stock is "Buy." The 12-month stock price forecast is $236.67, which is an increase of 0.08% from the latest price.
News
National Campaign Launches to Combat Diabetes Stigma Using Comedy
SAN FRANCISCO , Oct. 10, 2024 /PRNewswire/ -- The Spoonful of Laughter campaign is a national initiative using comedy to educate about diabetes, counter harmful stereotypes and stigma, and amplify aut...
Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced p...
Upstart, Insulet And 2 Other Stocks Executives Are Selling
The Nasdaq 100 closed higher by over 400 points during Wednesday's session. Investors, meanwhile, focused on some notable insider trades.
What Helped Insulet Stock Gain 10% This Week?
Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over...
S&P 500 Gains and Losses Today: Medical Device Makers ResMed, Insulet Lead Index
Major U.S. equities indexes ticked higher ahead of a potentially consequential earnings report from semiconductor giant Nvidia (NVDA) as well as key inflation and economic data set for release later i...
This Healthcare Stock Is the Best Performer in the S&P 500 Tuesday
Insulet got a key FDA approval for an insulin delivery system.
Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise
Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled Tuesday after a study showed that a popular drug made by Eli Lilly (LLY) ...
Insulet to Present at Upcoming Investor Conferences
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management ...
Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted a gr...
Insulin Pump Maker Insulet's Stock Slumps on User Growth Concerns
Shares of Insulet (PODD) suffered the heaviest losses of any S&P 500 stock on Friday, dropping 8.8% after the maker of insulin management devices suggested new user growth could be lower than previous...
Insulet Is the Worst Stock in S&P 500 Today, Despite Solid Earnings. Here's Why.
The automated insulin technology developer stock is on track for its largest percentage decline since February.
Insulin Pump Maker Insulet's Growth Catalysts Set to Boost Revenue in 2025: Analyst
Insulin device maker Insulet Corporation PODD reported a second-quarter adjusted EPS of $0.55 on Thursday, missing the consensus estimate of $0.56. It reported an EPS of $0.38 a year ago.
Insulet Corporation (PODD) Q2 2024 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President & Ch...
Insulet inventory pressures cloud annual revenue forecast raise
Insulet Corp PODD.O on Thursday raised its annual revenue growth forecast but pressures over unutilised inventory clouded the upbeat outlook, sending shares of the insulin device maker down about 3.5%...
Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced f...
Insulet expects to beat revenue estimates on strong insulin pump demand
Insulet reported preliminary second-quarter revenue above Wall Street estimates on Friday, as it benefited from strong demand for its insulin delivery devices.
Insulet Reports Preliminary Second Quarter 2024 Revenue Results
ACTON, Mass.--(BUSINESS WIRE)--Insulet Reports Preliminary Second Quarter 2024 Results.
Insulet to Announce Second Quarter 2024 Financial Results on August 8, 2024
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced p...
Insulet's SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today shared posi...
Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...
Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today made severa...
Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023
Insulet Corporation saw a significant drop in stock price in 2023 due to concerns over the impact of GLP-1 weight loss drugs on the insulin pump industry. These fears seem to be largely overblown, how...
Insulet to Present at the Jefferies Global Healthcare Conference
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management ...
Insulet Corporation (PODD) Q1 2024 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President and Chi...